Molecular pathways: Targeted α - Particle radiation therapy

Clinical Cancer Research

Volumn 19, Issue 3, 2013, Pages 530-537

  Baidoo, Kwamena E ^a   Yong, Kwon ^a   Brechbiel, Martin W ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ACTINIUM 225; ANTINEOPLASTIC AGENT; ASTATINE 211; BISMUTH 213; CD138 ANTIBODY; CD20 ANTIBODY; CH81C6 ANTIBODY AT 211; CYTARABINE; DOXORUBICIN; GEMCITABINE PB 212; GEMTUZUMAB OZOGAMICIN; LEAD 212; LINTUZUMAB AC 225; LINTUZUMAB BI 213; MONOCLONAL ANTIBODY; MONOCLONAL ANTIBODY 9.2.27 BI 213; MONOCLONAL ANTIBODY D9; MONOCLONAL ANTIBODY MX35 F(AB')2 FRAGMENT AT 211; PACLITAXEL; PLACEBO; RADIOPHARMACEUTICAL AGENT; RADIUM CHLORIDE RA 223; SUBSTANCE P BI 213; TRASTUZUMAB PB 212; UNCLASSIFIED DRUG;

ABSENCE OF SIDE EFFECTS; ACUTE GRANULOCYTIC LEUKEMIA; ALPHA RADIATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; BONE METASTASIS; BRAIN TUMOR; CANCER CELL CULTURE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CELL CYCLE CHECKPOINT; CELL DEATH; CELL SURVIVAL; COLON CANCER; CYTOREDUCTIVE SURGERY; CYTOTOXICITY; DNA FRAGMENTATION; DNA STRAND BREAKAGE; DOSE RESPONSE; DOSIMETRY; DRUG DOSE ESCALATION; DRUG EXCRETION; DRUG SAFETY; DRUG SENSITIVITY; GLIOBLASTOMA; GLIOMA; HUMAN; IN VITRO STUDY; IONIZING RADIATION; ISOTOPE LABELING; LEUKOPENIA; LINEAR ENERGY TRANSFER; LIVER TOXICITY; LOW DRUG DOSE; METASTASIS; METASTATIC MELANOMA; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; NEPHROTOXICITY; NEUTROPHILIA; NONHODGKIN LYMPHOMA; NONHUMAN; OVARY CANCER; OVARY CARCINOMA; PANCREAS CANCER; PRIORITY JOURNAL; RADIATION DOSE; RADIATION NECROSIS; RADIOACTIVITY; RADIOISOTOPE THERAPY; RADIOSENSITIVITY; RECURRENT CANCER; THROMBOCYTOPENIA; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ALPHA PARTICLES; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; SIGNAL TRANSDUCTION;

EID: 84873350765     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-12-0298     Document Type: Article

References (41)

1. Mazerona JJ, Gerbaulet A. The centenary of discovery of radium. Radiotherapy Oncol 1998;49:205-16.
2. Bruland OS, Jonasdottir TJ, Fisher DR, Larsen RH. Radium-223: From radiochemical development to clinical applications in targeted cancer therapy. Curr Radiopharm 2008;1:203-8.
3. 224Ra] radium chloride therapy for ankylosing spondylitis (Bekhterev's disease). Med Klin (Munich) 2007;102:540-9.
4. Kim YS, Brechbiel MW. An overview of targeted alpha therapy. Tumor Biol 2012;33:573-90.
5. McDevitt MR, Sgouros G, Finn RD, Humm JL, Jurcic JG, Larson SM, et al. Radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med 1998;25:1341-51.
6. Zalutsky MR, Pruszynski M. Astatine-211: production and availability. Curr Radiopharm 2011;4:177-85.
7. 212Pb as a clinical therapeutic: getting the lead in! Dalton Trans 2011;40:6068-76.
8. Franken NAP, Hovingh S, Ten Cate R, Krawczyk P, Stap J, Hoebe R, et al. Relative biological effectiveness of high linear energy transfer a-particles for the induction of DNA-double-strand breaks, chromosome aberrations and reproductive cell death in SW-1573 lung tumour cells. Oncol Rep 2012;27:769-74.
9. Soyland C, Hassfjell SP. Survival of human lung epithelial cells following in vitro α-particle irradiation with absolute determination of the number of α-particle traversals of individual cells. Int J Radiat Biol 2000;76:1315-22.
10. Pouget JP, Mather SJ. General aspects of the cellular response to low-and high-LET radiation. Eur J Nucl Med 2001;28:541-61.
11. Friesen C, Glatting G, Koop B, Schwarz K, Morgenstern A, Apostolidis C, et al. Breaking chemoresistance and radioresistance with [213Bi]anti-CD45 antibodies in leukaemia cells. Cancer Res 2007;67:1950-8
12. Janssens S, Tschopp J. Signals from within: the DNA damage-induced NF-kappaB response. Cell Death Differ 2006;13:773-84.
13. Thompson LH. Recognition, signaling, and repair of DNA doublestrand breaks produced by ionizing radiation in mammalian cells: The molecular choreography. Mutation Res 2012;751:158-246.
14. 211At anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin. Eur J Nucl Med Mol Imaging 2010;37:851-61.
15. 211At a-particle irradiation on expression of selected radiation responsive genes in human lymphocytes. Int J Radiat Biol 2009;85:403-12.
16. Macklis RM, Lin JY, Beresford B, Atcher RW, Hines JJ, Humm JL. Cellular kinetics, dosimetry, and radiobiology of a-particle radioimmunotherapy: Induction of apoptosis. Radiat Res 1992;130: 220-6.
17. Supiot S, Gouard S, Charrier J, Apostolidis C, Chatal JF, Barbet J, et al. Mechanisms of cell sensitization to a radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005;11:7047s-52s.
18. 213Bi-immunoconjugates in HSC45-M2 gastric cancer cells is different from apoptotic cell death. Eur J Nucl Med Mol Imaging 2005;32:274-85.
19. Seidl C, Port M, Apostolidis C, Bruchertseifer F, Schwaiger M, Senekowitsch-Schmidtke R, et al. Differential gene expression triggered by highly cytotoxic a-emitter-immunoconjugates in gastric cancer cells. Invest New Drugs 2010;28:49-60.
20. 212Pb- Radioimmunotherapy induces G2 cell cycle arrest and delays DNA damage repair in tumor xenografts in a model for disseminated intraperitoneal disease. Mol Cancer Ther 2012;11:639-48.
21. 212Pb-radioimmunotherapy by gemcitabine involves initial abrogation of G2 arrest and blocked DNA damage repair by interference with Rad51. Int J Radiat Oncol Biol Phys 2012 Nov 29. [Epub ahead of print].
22. Teshima T, Owen JB, Hanks GE, Sato S, Tsunemoto H, Inoue T. A comparison of the structure of radiation oncology in the United States and Japan. Int J Radiat Oncol Biol Phys 1996;34:243-50.
23. Physician Characteristics and Distribution in the U.S., 2008 Edition. [last updated 2012 Nov 6]. Available from: https://www.astro.org/News-and-Media/ Media-Resources/FAQs/Fast-Facts-About-Radiation-Therapy/Index.aspx.
24. Bonner JA, Harari PM, Giralt J, Azarnia N, Shin DM, Cohen RB, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. N Engl J Med 2006;354:567-78.
25. Hagenbeek A. VIII. Radioimmunotherapy in malignant lymphoma: an underused tool? Ann Oncol 2011;22 Suppl 4:iv51-3.
26. Haro KJ, Scott AC, Scheinberg DA. Mechanisms of resistance to high and low linear energy transfer radiation in myeloid leukemia cells. Blood 2012;120:2087-97.
27. Zalutsky MR, McLendon RE, Garg PK, Archer GE, Schuster JM, Bigner DD. Radioimmunotherapy of neoplastic meningitis in rats using an a-particle emitting immunoconjugate. Cancer Res 1994; 54:4719-25.
28. 211Atlabeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med 2008;49:30-8.
29. 2 - a phase I study. J Nucl Med 2009;50:1153-60.
30. 225Ac-HuM195, in nonhuman primates. J Nucl Med 2004;45:129-37.
31. ClinicalTrials.gov (2011). Targeted atomic nano-generators (Actinium-225-labeled humanized anti-CD33 monoclonal antibody HuM195) in patients with advanced myeloid malignancies. [cited 2011 Jun 9]. Available from: http://clinicaltrials.gov/show/NCT00672165.
32. Jurcic J. Memorial Sloan-Kettering. Personal communication.
33. 213Bi-labeled anti-CD19 and anti-CD20-CHX-A"-DTPA conjugates. ACS Meeting Abstracts 2009;225:U261.
34. Raja C, Graham P, Rizvi SMA, Song E, Goldsmith H, Thompson J, et al. Interim analysis of toxicity and response in phase I trial of systemic targeted alpha therapy for metastatic melanoma. Cancer Biol Ther 2007;6:846-52.
35. Jurcic JG, Larson SM, Sgouros G, McDevitt MR, Finn RD, Divgi CR, et al. Targeted a particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
36. Rosenblat TL, McDevitt MR, Mulford DA, Pandit-Taskar N, Divgi CR, Panageas KS, et al., Sequential cytarbine and a-particle immunotherapy with bismuth-213-lintuzumab (HuM195) for acute myeloid leukemia. Clin Cancer Res 2010;16:5303-11.
37. Kneifel S, Cordier D, Good S, Ionescu MCS, Ghaffari A, Hofer S, et al. Local targeting of malignant gliomas by the diffusible peptidic vector 1,4,7,10-tetraazacyclododecane-1-glutaric acid-4,7,10-triacetic acid-substance P. Clin Cancer Res 2006;12:3843-50.
38. 11]-substance P: a pilot trial. Eur J Nucl Med Mol Imaging 2010;37:1335-44.
39. Bourdet P. AREVA Med. Personal communication.
40. Parker C, Aksnes A, Haugen I, Bolstad B, Nilsson S. Radium-223 chloride, a novel, highly targeted alpha-pharmaceutical for treatment of bone metastases from castration-resistant prostate cancer (CRPC): hematologic and safety profile with repeated dosing. Ann Oncol 2010;21Suppl 8:277-8.
41. Yong K. National Cancer Institute. Personal communication.